Selexis SA, a JSR Life Sciences Company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative biologic medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 164 products in preclinical and clinical development and 10 commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. In June 2017, Selexis became part of the JSR Life Sciences group. JSR’s contract development and manufacturing organization (CDMO) service offering leverages the full capabilities of Selexis’ proprietary SUREtechnology Platform™ to offer an end-to-end solution to industry. More information is available at www.selexis.com. The SUREtechnology Platform™ incorporates a number of proprietary technologies that are unique to Selexis: ADVANCED GENE TRANSFECTION TECHNOLOGY AND PROCEDURES - Selexis SGE® (Selexis Genetic Elements) - SUREtech Vectors™ MEDIA AND FEED STRATEGIES PROPRIETARY CHO-K1 CELL LINE - Selexis SURE CHO-M Cell Line™ (CHO-K1) GENOME AND TRANSCRIPTOME - SURE CHO-Mplus Libraries™ - SUREscan® Selexis is a science-driven organization, founded on the academic interests and discoveries of its core scientific team in molecular biology, cellular physiology, and genetic engineering, and is committed to the application of these insights and methods to continuous process improvement and practical problem-solving through close interaction with its industry clients and collaborators. Global clients, representing the complete spectrum of life science enterprises—from research laboratories and biotech startups to Big Pharma—have utilized the unparalleled proprietary technology and highly specialized services of Selexis.